Trial Profile
A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Algeta; Bayer
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 19 Feb 2011 Results were presented in combination with results from the BC1-02 study (59651) at the 2011 Genitourinary Cancers Symposium.
- 24 Sep 2010 New trial record